DAFTAR PUSTAKA

Alsayed, S. S. R., & Gunosewoyo, H. (2023). Tuberculosis: Pathogenesis, Current Treatment Regimens and New Drug Targets. *International Journal of Molecular Sciences*, *24*(6). https://doi.org/10.3390/ijms24065202

Amanda, G. (2018). Peran Aerosol M. Tuberculosis pada Penyebaran Infeksi Tuberkulosis. *Cermin Dunia Kedokteran*, *45*(1), 62–65. https://www.neliti.com/publications/401250/

BañUls, A. L., Sanou, A., Van Anh, N. T., & Godreuil, S. (2015). Mycobacterium tuberculosis: Ecology and evolution of a human bacterium. *Journal of Medical Microbiology*, *64*(11), 1261–1269. https://doi.org/10.1099/jmm.0.000171

Chamberlain, P. D., Sadaka, A., Berry, S., & Lee, A. G. (2017). Ethambutol optic neuropathy. *Current Opinion in Ophthalmology*, *28*(6), 545–551. https://doi.org/10.1097/ICU.0000000000000416

Fraga, A. D. S. S., Oktavia, N., & Mulia, R. A. (2021). Evaluasi Penggunaan Obat Anti Tuberkulosis Pasien Baru Tuberkulosis Paru Di Puskesmas Oebobo Kupang. *Jurnal Farmagazine*, *8*(1), 17. https://doi.org/10.47653/farm.v8i1.530

Ginting, A. N., Silitonga, K., Suliati, S., & Murtiani, F. (2022). Profil Tuberkulosis Paru Pada Anak di RSPI Prof. Dr. Sulianti Saroso. *The Indonesian Journal of Infectious Diseases*, *8*(1), 21–34. https://doi.org/10.32667/ijid.v8i1.134

Glaziou, P., Sismanidis, C., & Floyd, K. (2021). Global Epidemiology of Tuberculosis. *Essential Tuberculosis*, 341–348. https://doi.org/10.1007/978-3-030-66703-0_37

Humayun, M., Chirenda, J., Ye, W., Mukeredzi, I., Mujuru, H. A., & Yang, Z. (2022). Effect of Gender on Clinical Presentation of Tuberculosis (TB) and Age-Specific Risk of TB, and TB-Human Immunodeficiency Virus Coinfection. *Open Forum Infectious Diseases*, *9*(10), ofac512. https://doi.org/10.1093/ofid/ofac512

Ismail, Baharuddin, Sukriyadi, Basri, M., & Yulianto. (2023). Kapasitas Fungsional Paru Pasien Tuberkulosis Paru Pulmonary Functional Capacity Of Tuberculosis Patients. *Politeknik Kesehatan Makassar*, *14*(2), 2087–2122.

Ismaya, N. A. (2024). Evaluasi Penggunaan Obat Anti Tuberculosis Paru Pada Pasien Aids Di Instalasi Rawat Jalan Rumah Sakit Umum Kota Tangerang Selatan. *Prosiding Semlitmas (Seminar Hasil Penelitian Dan Pengabdian Masyarakat)*, *1*(1), 70–82.

Kartasasmita, C. B. (2016). Epidemiologi Tuberkulosis. *Sari Pediatri*, *11*(2), 124. https://doi.org/10.14238/sp11.2.2009.124-9

Kasni, Hanafi, L. O. A., & Fauziah, R. (2024). Rasionalitas Penggunaan Obat

Anti Tuberkulosis Pada Pasien Tuberkulosis Paru Di Puskesmas Poasia Kota Kendari Tahun 2021. *Jurnal Pharmacia Mandala Waluya*, *3*(1), 1–11. https://doi.org/10.54883/jpmw.v3i1.88

Kemenkes RI. (2016). *Peraturan Menteri Kesehatan Republik Indonesia Nomor 67 Tahun 2016 Tentang Penanggulangan Tuberkulosis*.

Kemenkes RI. (2020a). Permenkes No 3 Tahun 2020 Tentang Klasifikasi dan Perizinan Rumah Sakit. *Tentang Klasifikasi Dan Perizinan Rumah Sakit*, *3*, 1–80. http://bppsdmk.kemkes.go.id/web/filesa/peraturan/119.pdf

Kemenkes RI. (2020b). Strategi Nasional Penanggulangan Tuberkulosis di Indonesia 2020-2024. *Pertemuan Konsolidasi Nasional Penyusunan STRANAS TB*, 135.

Kementerian Kesehatan Indonesia, D. J. P. dan P. (2023). Laporan Program Penanggulangan Tuberkulosis Tahun 2022. *Kemenkes RI*, 1–147. https://tbindonesia.or.id/pustaka_tbc/laporan-tahunan-program-tbc-2021/

Koch, A., Mizrahi, V., & Warner, D. F. (2014). The impact of drug resistance on Mycobacterium tuberculosis physiology: What can we learn from rifampicin? *Emerging Microbes and Infections*, *3*(September 2013). https://doi.org/10.1038/emi.2014.17

Kristiyowati, A. D. (2020). Rasionalitas Penggunaan Obat Ditinjau Dari Indikator Peresepan World Health Organization (WHO) di Rumah Sakit IMC Periode Januari - Maret 2019. *Prosiding Senantias*, *1*(1), 277–286. http://openjournal.unpam.ac.id/index.php/Senan/article/view/8205

Monintja N, Warouw F, P. O. (2020). Hubungan Antara Kondisi Fisik rumah dengan kejadian tuberkulosis paru. *Indonesian Journal of Public Health and Community Medicine*, *1*(3), 94–100.

Nhamoyebonde, S., & Leslie, A. (2014). Biological Differences Between the Sexes and Susceptibility to Tuberculosis. *The Journal of Infectious Diseases*, *209*(suppl_3), S100–S106. https://doi.org/10.1093/infdis/jiu147

Nurhayati, A., Rahayuningsih, N., & Alifiar, I. (2020). Analisis Kualitas Hidup (Qoly) Dan Kepatuhan Terapi Pada Pasien Tuberkulosis Paru Di Rumah Sakit X Kota Tasikmalaya. *Analisis Kualitas Hidup ... Journal Of Pharmacopolium*, *3*(3), 183–189.

Nuryadin Zain, D., Pebiansyah, A., Yuliana, A., Amin, S., Rahmiyani, I., Alifiar, I., Hidayat, T., & Resmawati Shaleha, R. (2024). *Penyuluhan Pencegahan DBD di PC Persistri Kota Tasikmalaya*. *8*(3), 2701–2709. http://journal.ummat.ac.id/index.php/jmm

Pai, M., Dewan, P. K., & Swaminathan, S. (2023). Transforming tuberculosis diagnosis. *Nature Microbiology*, *8*(5), 756–759. https://doi.org/10.1038/s41564-023-01365-3

Palanivel, J., Sounderrajan, V., Thangam, T., Rao, S. S., Harshavardhan, S., & Parthasarathy, K. (2023). Latent Tuberculosis: Challenges in Diagnosis and

Treatment, Perspectives, and the Crucial Role of Biomarkers. *Current Microbiology*, *80*(12), 392. https://doi.org/10.1007/s00284-023-03491-x

Ragonnet, R., Trauer, J. M., Geard, N., Scott, N., & McBryde, E. S. (2019). Profiling Mycobacterium tuberculosis transmission and the resulting disease burden in the five highest tuberculosis burden countries. *BMC Medicine*, *17*(1), 1–12. https://doi.org/10.1186/s12916-019-1452-0

Ranti, Y. paula. (2021). Biofarmasetikal Tropis Biofarmasetikal Tropis. *The Tropical Journal of Biopharmaceutical*, *2*(2), 158–169.

Renny, A. N., & Beni, P. (2016). Analisis dan Perancangan Sistem Informasi Rekam Medis Di Rumah Sakit Tk. IV dr. Bratanata Jambi. *Jurnal Manajemen Sistem Informatika*, *1*(2), 147–158.

Rodríguez-Marco, N. A., Solanas-Álava, S., Ascaso, F. J., Martínez-Martínez, L., Rubio-Obanos, M. T., & Andonegui-Navarro, J. (2014). Neuropatía óptica severa y reversible por etambutol e isoniazida. *Anales Del Sistema Sanitario de Navarra*, *37*(2), 287–291. https://doi.org/10.4321/s1137-66272014000200012

Syafa'ah, I., & Yudhawati, R. (2019). Peran Imunitas Mukosa terhadap Infeksi Mycobacterium Tuberculosis. *Jurnal Respirasi*, *2*(2), 61. https://doi.org/10.20473/jr.v2-i.2.2016.61-68

Tamunu, M. sarra, Pareta, D. N., Hariyadi, H., & Karauwan, F. A. (2022). Skrining Fitokimia Dan Uji Aktivitas Antioksidan Ekstrak Daun Benalu Pada Kersen Dendrophtoe pentandra (L.) Dengan Metode 2,2- diphenyl -1-Picrylhydrazyl (DPPH). *Biofarmasetikal Tropis*, *5*(1), 79–82. https://doi.org/10.55724/jbiofartrop.v5i1.378

Verma, J. S., Gupta, Y., Nair, D., Manzoor, N., Rautela, R. S., Rai, A., & Katoch, V. M. (2014). Evaluation of gidB alterations responsible for streptomycin resistance in Mycobacterium tuberculosis. *Journal of Antimicrobial Chemotherapy*, *69*(11), 2935–2941. https://doi.org/10.1093/jac/dku273

Wang, P., Pradhan, K., Zhong, X. bo, & Ma, X. (2016). Isoniazid metabolism and hepatotoxicity. *Acta Pharmaceutica Sinica B*, *6*(5), 384–392. https://doi.org/10.1016/j.apsb.2016.07.014

Widodo, W., Irianto, A., & Pramono, H. (2017). Karakteristik Morfologi Mycobacterium tuberculosis yang Terpapar Obat Anti TB Isoniazid (INH) secara Morfologi. *Biosfera*, *33*(3), 109. https://doi.org/10.20884/1.mib.2016.33.3.316

World Health Organization. (2024). *World health sWORLD HEALTH ORGANIZATION - World health statistics 2024. ISBN 9789240094703. tatistics 2024*.

World Organization for Animal Health. (2023). Report 20-23. In *January: Vol. t/malaria/* (Issue March).

Zhang, Y., Shi, W., Zhang, W., & Mitchison, D. (2015). Mechanisms of

pyrazinamide action and resistance. *Molecular Genetics of Mycobacteria*, *1952*(2), 479–491. https://doi.org/10.1128/9781555818845.ch24